Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Bristol-Myers Squibb will sell its pipeline of investigational HIV medicines to ViiV Healthcare for $350 million plus potentially more than $2 billion in milestone payments. BMS, a pioneer in HIV drug discovery, says the deal is in keeping with its decision, announced in June 2015, to discontinue virology drug discovery. ViiV was formed in 2009 to combine the HIV drug businesses of GlaxoSmithKline and Pfizer.
This article has been sent to the following recipient: